The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 1, Pages 75
Publisher
MDPI AG
Online
2020-12-24
DOI
10.3390/ijms22010075
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody
- (2020) Hirofumi Ohmura et al. BRITISH JOURNAL OF CANCER
- FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
- (2020) Matthew Kraman et al. CLINICAL CANCER RESEARCH
- Expression patterns of immune checkpoints in acute myeloid leukemia
- (2020) Cunte Chen et al. Journal of Hematology & Oncology
- Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma
- (2020) Florian Gebauer et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis
- (2020) Mengzhou Guo et al. Journal of Translational Medicine
- Stromal LAG-3+cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture
- (2020) Han Zeng et al. Journal for ImmunoTherapy of Cancer
- Correlation Between Tumor-Associated Macrophage and Immune Checkpoint Molecule Expression and Its Prognostic Significance in Cutaneous Melanoma
- (2020) Young Jae Kim et al. Journal of Clinical Medicine
- M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
- (2020) Michal Hensler et al. Journal for ImmunoTherapy of Cancer
- NR4A transcription factors limit CAR T cell function in solid tumours
- (2019) Joyce Chen et al. NATURE
- Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction
- (2019) Xindong Liu et al. NATURE
- Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation
- (2019) Takeo K. Maeda et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- TOX is a critical regulator of tumour-specific T cell differentiation
- (2019) Andrew C. Scott et al. NATURE
- TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
- (2019) Omar Khan et al. NATURE
- TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion
- (2019) Hyungseok Seo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent
- (2019) Broos et al. Cancers
- Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming
- (2019) Aimee Merino et al. JOURNAL OF CLINICAL INVESTIGATION
- Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3 Knock-In Mice
- (2019) Elena Burova et al. MOLECULAR CANCER THERAPEUTICS
- LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer
- (2019) Cinzia Solinas et al. Cancers
- Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use
- (2019) Quentin Lecocq et al. Biomolecules
- Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis
- (2019) Ramy R. Saleh et al. Frontiers in Oncology
- Characterization of LAG-3, CTLA-4, and CD8+ TIL density and their joint influence on the prognosis of patients with esophageal squamous cell carcinoma
- (2019) Wenjia Wang et al. Annals of Translational Medicine
- Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia
- (2018) Marina Wierz et al. BLOOD
- LAG-3 Inhibitory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells
- (2018) Andreia C. Lino et al. IMMUNITY
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
- (2018) Katrijn Broos et al. Theranostics
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Soluble LAG3 acts as a potential prognostic marker of gastric cancer and its positive correlation with CD8+T cell frequency and secretion of IL-12 and INF-γ in peripheral blood
- (2018) Na Li et al. Cancer Biomarkers
- Abstract 3033: Immuno-PET detection of LAG-3 expressing intratumoral lymphocytes using the zirconium-89 radiolabeled fully human anti-LAG-3 antibody REGN3767
- (2018) Marcus P. Kelly et al. CANCER RESEARCH
- Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma
- (2018) Sarah Harris-Bookman et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
- (2018) David S. Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
- (2018) Robin Maximilian Awad et al. Frontiers in Immunology
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
- (2018) Takumi Maruhashi et al. NATURE IMMUNOLOGY
- 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
- (2018) Frederike Bensch et al. NATURE MEDICINE
- Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
- (2018) A. N. Niemeijer et al. Nature Communications
- Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia
- (2017) Mika Shapiro et al. HAEMATOLOGICA
- Ablation of Transcription Factor IRF4 Promotes Transplant Acceptance by Driving Allogenic CD4 + T Cell Dysfunction
- (2017) Jie Wu et al. IMMUNITY
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- Improved Debulking of Peritoneal Tumor Implants by Near-Infrared Fluorescent Nanobody Image Guidance in an Experimental Mouse Model
- (2017) Pieterjan Debie et al. MOLECULAR IMAGING AND BIOLOGY
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma
- (2017) Zhi-Zhang Yang et al. Oncotarget
- Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia
- (2017) Mika Shapiro et al. HAEMATOLOGICA
- Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients
- (2017) Xiaofang Xing et al. OncoImmunology
- Galectin 3 as a guardian of the tumor microenvironment
- (2016) Peter P. Ruvolo BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Abstract 3217: MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART®) protein with T-cell immunomodulatory activity for cancer treatment
- (2016) Ross LaMotte-Mohs et al. CANCER RESEARCH
- Pathological -synuclein transmission initiated by binding lymphocyte-activation gene 3
- (2016) X. Mao et al. SCIENCE
- Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
- (2016) Ruea-Yea Huang et al. OncoImmunology
- IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivo
- (2016) Joanna S. Kritikou et al. Scientific Reports
- Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis
- (2015) Haiming Yu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
- (2015) N. A. Giraldo et al. CLINICAL CANCER RESEARCH
- Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial
- (2015) A. Legat et al. CLINICAL CANCER RESEARCH
- The Transcription Factor NFAT Promotes Exhaustion of Activated CD8 + T Cells
- (2015) Gustavo J. Martinez et al. IMMUNITY
- Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
- (2015) M. Keyaerts et al. JOURNAL OF NUCLEAR MEDICINE
- TGF-β3-expressing CD4+CD25−LAG3+ regulatory T cells control humoral immune responses
- (2015) Tomohisa Okamura et al. Nature Communications
- LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
- (2015) Ruea-Yea Huang et al. Oncotarget
- Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
- (2015) T. Kouo et al. Cancer Immunology Research
- LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
- (2014) F. Xu et al. CANCER RESEARCH
- Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II
- (2014) Bitao Liang et al. JOURNAL OF IMMUNOLOGY
- Trafficking of LAG-3 to the Surface on Activated T Cells via Its Cytoplasmic Domain and Protein Kinase C Signaling
- (2014) Joonbeom Bae et al. JOURNAL OF IMMUNOLOGY
- Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3
- (2014) Chiara Camisaschi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial
- (2014) Emanuela Romano et al. Journal of Translational Medicine
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- (2014) Nicolas J. Llosa et al. Cancer Discovery
- Nanobody: The “Magic Bullet” for Molecular Imaging?
- (2014) Rubel Chakravarty et al. Theranostics
- Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
- (2013) H-B Jie et al. BRITISH JOURNAL OF CANCER
- Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations
- (2013) Haoyu Sun et al. CYTOKINE
- Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
- (2013) S. R. Goding et al. JOURNAL OF IMMUNOLOGY
- Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells
- (2013) Nicola Gagliani et al. NATURE MEDICINE
- Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging
- (2012) Tengfei Li et al. FASEB JOURNAL
- Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC patients
- (2012) Fu-Jun Li et al. IMMUNOLOGY LETTERS
- A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
- (2012) Andrea Wang-Gillam et al. INVESTIGATIONAL NEW DRUGS
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional differences between low- and high-affinity CD8+T cells in the tumor environment
- (2012) Rinke Bos et al. OncoImmunology
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
- (2011) Taku Okazaki et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites
- (2010) C. Camisaschi et al. JOURNAL OF IMMUNOLOGY
- First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
- (2010) Chrystelle Brignone et al. Journal of Translational Medicine
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis
- (2009) C. J. Workman et al. JOURNAL OF IMMUNOLOGY
- CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2
- (2009) T. Okamura et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular cloning and expression analysis of pig lymphocyte activation gene-3 (LAG-3; CD223)
- (2009) Seon-Soo Kim et al. VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now